Skip to main content

Table 1 Patient and tumour characteristics (n = 13)

From: Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital

Variable (n = 13)

N (%)

Performance status (1 st line)

 

0

1 (7.7%)

1

12 (92.3%)

Menopausal status

 

Premenopausal

1 (7.7%)

Postmenopausal

12 (92.3%)

Number of comorbidities

 

0–1

11 (84.6%)

2–3

2 (15.4%)

Initial management at diagnosis

 

Surgical resection alone

5 (38.5%)

Surgical resection and BSO

8 (61.5%)

Prior exogenous estrogens

 

Tamoxifen

3 (23%)

HRT

7 (53.8%)

Prior pelvic radiotherapy

4 (30.8%)

Sites of metastases at time of 1 st line

 

Pelvic

6 (46.2%)

Extrapelvic

3 (23%)

Both pelvic and extrapelvic disease

4 (30.8%)

Tumour volume at 1 st line

 

Low

1 (7.7%)

High

12 (92.3%)

Number of metastases at 1 st line

 

Oligometastatic

5 (38.5%)

Multiple

8 (61.5%)

Hormone receptor status

 

ER

 

Moderate to strong (grade 2–3)

9 (69.2%)

Weak (grade 1)

0 (7.1%)

NA

4 (30.8%)

PgR

 

Moderate to strong (grade 2–3)

9 (69.2%)

Weak (grade 1)

0 (7.1%)

NA

4 (30.8%)

  1. BSO, bilateral salphigoophorectomy; HRT, hormonal replacement therapy; ER, estrogen receptor; PgR, progesterone receptor NA, not available.